Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Duality Biotherapeutics, Inc. ( (HK:9606) ) has provided an announcement.
Duality Biotherapeutics plans to issue up to 15,779,190 new ordinary shares denominated in RMB and list them on Shanghai’s Sci-Tech Board, subject to shareholder and regulatory approvals. The new RMB shares will be fully fungible with the company’s existing Hong Kong-listed shares, sharing the same par value, voting rights, and entitlement to dividends and assets.
The proposed offering, which may include an over-allotment option of up to 15% of the initial issuance, would represent no more than 15% of the enlarged share capital, excluding any over-allotment shares. By targeting qualified investors with SSE accounts and meeting Sci-Tech Board eligibility requirements, Duality aims to diversify its funding sources, increase liquidity, and strengthen its presence in mainland China’s capital markets.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$383.47 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a Cayman Islands-incorporated biopharmaceutical company listed in Hong Kong that focuses on developing innovative therapeutic products. Its shares are currently traded on the Hong Kong Stock Exchange, and the company is now seeking an additional listing channel on mainland China’s Sci-Tech Board to broaden its investor base and access onshore RMB capital.
Average Trading Volume: 815,049
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$27.31B
See more insights into 9606 stock on TipRanks’ Stock Analysis page.